Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta‐analysis

Brain and Behavior - Tập 8 Số 11 - 2018
Chao-feng Yang1,2, Zhiwei Guo2, Haitao Peng2, Guoqiang Xing2,3, Huaping Chen2, Morgan A. McClure2, Bin He2, Lin He2, Fei Du4, Liangwen Xiong5, Qiwen Mu2,6
1Chengdu 363 Hospital of Southwest Medical University, Chengdu, China
2Department of Radiology & Imaging Institute of Rehabilitation and Development of Brain Function The Second Clinical Medical College of North Sichuan Medical College Nanchong Central Hospital Nanchong China
3Lotus Biotech.com LLC, John Hopkins University-MCC, Rockville, Maryland
4Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts
5Department of Genitourinary, The University of Texas MD Anderson Cancer Center, Houston, Texas
6Peking University Third Hospital, Beijing, China

Tóm tắt

AbstractIntroduction

Therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) on motor recovery of Parkinson's disease (PD) have been reported; however, the protocols of these studies varied greatly. The aim of this meta‐analysis was to evaluate the optimal rTMS parameters for motor recovery of PD.

Methods

Electronic databases were searched for studies investigating the therapeutic effects of rTMS on motor function in patients with PD. The section III of the Unified Parkinson's Disease Rating Scale (UPDRS) was extracted as the primary outcome, and the standardized mean difference (SMD) with 95% confidence interval (CI) was calculated.

Results

Twenty‐three studies with a total of 646 participants were included. The pooled estimates of rTMS revealed significant short‐term (SMD, 0.37; p < 0.00001) and long‐term (SMD, 0.39; p = 0.005) effects on motor function improvement of PD. Subgroup analysis observed that high‐frequency rTMS (HFrTMS) was significant in improving motor function (SMD, 0.48; p < 0.00001), but low‐frequency rTMS (LFrTMS) was not. In particular, when HFrTMS targeted over the primary motor cortex (M1), in which the bilateral M1 revealed a larger effect size than unilateral M1. Compared to single‐session, multi‐session of HFrTMS over the M1 showed significant effect size. In addition, HFrTMS over the M1 with a total of 18,000–20,000 stimulation pulses yielded more significant effects (SMD, 0.97; p = 0.01) than other dosages.

Conclusions

In conclusion, multi‐session of HFrTMS over the M1 (especially bilateral M1) with a total of 18,000–20,000 pulses appears to be the optimal parameters for motor improvement of PD.

Từ khóa


Tài liệu tham khảo

10.1212/WNL.0b013e31820ce6bb

10.1177/1545968312445636

10.1007/978-3-7091-0579-5_7

10.1016/j.clinph.2006.03.033

10.1212/WNL.0000000000003279

10.1016/j.psychres.2014.05.010

10.1001/jamaneurol.2014.4380

10.1016/j.brs.2016.03.017

10.1097/WNP.0000000000000455

10.1016/S0140-6736(16)31012-1

Conditions TNCCfC. (2006).Symptomatic pharmacological therapy in Parkinson's disease. Royal College of Physicians (UK).

10.1016/S1474-4422(06)70471-9

10.1016/j.clinph.2006.09.002

10.1136/bmj.315.7109.629

10.1007/s00415-014-7572-8

10.1002/mds.22364

10.1002/mds.22348

10.1016/j.parkreldis.2015.11.009

10.1136/jnnp.2005.069849

10.1007/s00415-011-5923-2

10.1002/mds.22168

Higgins J. G. S.(2011).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: The Cochrane Collaboration. Retrieved fromhttp://wwwcochranehandbookorg.

10.1161/STROKEAHA.111.649756

10.1016/j.neuron.2004.12.033

10.1136/jnnp.2007.131045

10.1002/ana.410320608

10.1046/j.1468-1331.2003.00649.x

10.1002/mds.21089

10.3233/RNN-140489

10.1097/PHM.0b013e3181d8a5b1

10.1212/01.wnl.0000172861.36430.95

10.1016/j.clinph.2004.05.025

10.1385/MN:29:2:117

10.1002/wps.20199

10.3233/JAD-150346

10.1002/mds.20713

10.1016/S1388-2457(99)00323-5

10.1016/j.brs.2013.05.002

10.1038/nature02617

10.1186/1471-2288-1-2

10.1007/s00702-013-1100-3

10.1002/mds.10370

10.1016/j.clinph.2004.02.005

Platz T., 2010, Brain stimulation and brain repair–rTMS: From animal experiment to clinical trials–what do we know?, Restorative Neurology and Neuroscience, 28, 387, 10.3233/RNN-2010-0570

10.1002/ana.410320206

10.1093/brain/120.1.103

10.1016/0166-4328(83)90191-2

10.3109/02699052.2014.947626

10.1007/s00702-009-0259-0

10.1212/WNL.0b013e31828c2f66

10.1016/S0022-510X(00)00370-1

10.1523/JNEUROSCI.21-15-j0003.2001

10.1093/brain/awg268

10.1016/j.eurpsy.2016.11.002

10.1016/j.pmrj.2015.08.009

10.1002/mds.23695

10.1016/j.jocn.2017.09.023

10.1002/mds.26206

10.1017/neu.2014.43

10.1093/bioinformatics/bti536